Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine
Capture System will be administered in children, adolescents and young adults (CAYA) with
refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell
Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ
transplant.
Funding Source: FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Collaborators:
Children's Hospital of Philadelphia Johns Hopkins University Medical College of Wisconsin Nationwide Children's Hospital University of California, San Francisco